Access Statistics for Paul Vincent Grootendorst

Author contact details at EconPapers.

Working Paper File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
A review of instrumental variables estimation in the applied health sciences 0 0 5 675 0 0 9 1,653
An Empirical Analysis of Milk Addiction 0 0 0 0 0 0 1 256
An Empirical Examination of the Patented Medicine Prices Review Board Price Control Amendments on Drug Launches in Canada 0 0 0 2 0 1 3 12
Beneficiary Cost Sharing Under Canadian Provincial Prescription Drug Benefit Programs: History and Assessment 0 0 1 109 0 0 3 364
Do Drug Plans Matter? Effects of Drug Plan Eligibility on Drug Use Among the Elderly, Social Assistance Recipients and the General Population 0 0 2 115 0 0 3 608
Do Drug Plans Matter? Effects of Drug Plan Eligibility on Drug Use Among the Elderly, Social Assistance Recipients and the General Population 0 0 2 63 0 1 4 350
Does It Matter Whom and How You Ask? Inter and Intra-rater Agreement in the Ontario Health Survey 0 0 0 9 0 0 1 78
Does rising income inequality affect mortality rates in advanced economies? 0 0 1 40 0 0 1 88
Economic Instruments for Obesity Prevention: Results of a Scoping Review and Modified Delphi Survey 0 0 0 55 0 0 2 257
Effects of 'Authorized-Generics' on Canadian Drug Prices 0 0 2 236 0 2 8 1,090
Evidence of Construct Validity for Stoke and Arthritis in a Population Health Survey 0 0 1 31 0 0 3 259
Financial Incentives to Dispense Low-Cost Drugs: A Case Study of British Columbia Pharmacare 0 0 0 56 0 0 4 442
Health Utilities Index Mark 3: Evidence of Construct Validity for Stroke and Arthritis in a Population Health Survey 0 0 0 25 0 0 1 104
How should we support pharmaceutical innovation? 0 1 1 214 0 3 9 562
Intellectual Property Protection And Drug Plan Coverage: Evidence From Ontario 0 0 1 33 0 1 4 105
International Experience With Pharmaceutical Policy: Common Challenges and Lessons for Canada 0 0 1 82 0 0 2 289
National Catastrophic Drug Insurance Revisited: Who Would Benefit from Senator Kirby's Recommendations? 0 0 0 57 0 0 1 518
National Catastrophic Drug Insurance Revisited: Who Would Benefit from Senator Kirby's Recommendations? 0 0 0 49 1 2 5 297
New Approaches to Rewarding Pharmaceutical Innovation 0 0 1 94 0 0 1 165
On Becoming 65 in Ontario: Effects of Provincial Drug Plan Eligibility on Utilization of Prescription Medicines 0 0 0 19 0 0 1 86
Out-of-Pocket Prescription Drug Expenditures and Public Prescription Drug Programs 0 0 0 53 0 0 0 341
Out-of-Pocket Prescription Drug Expenditures and Public Prescription Drug Programs 0 0 0 173 0 0 0 473
Out-of-Pocket Prescription Drug Expenditures and Public Prescription Drug Programs 0 0 0 99 0 1 2 486
Patents, Public-Private Partnerships or Prizes – How should we support pharmaceutical innovation? 1 1 1 200 1 1 7 580
Results of an Investigation into the Integrity of the Ontario Health Survey 0 0 0 4 0 0 2 93
The Effects of Drug Subsidies on Out-of Pocket Prescription Drug Expenditures by Seniors: Regional Evidence from Canada 0 0 0 74 0 0 0 581
The Effects of Drug Subsidies on Out-of Pocket Prescription Drug Expenditures by Seniors: Regional Evidence from Canada 0 0 0 139 0 1 1 825
The Effects of Drug Subsidies on Out-of-Poket Prescription Drug Expenditures by seniors: regional Evidence from Canada 0 0 0 29 0 0 1 560
The Impact of Differential Cost Sharing of Non-Steroidal Anti-Inflammatory Agents on the Use and Costs of Analgesic Drugs 0 0 1 106 0 0 1 982
The Impact of Reference Pricing of Cardiovascular Drugs on Health Care Costs and Health Outcomes: Evidence from British Columbia -- Volume I: Summary 0 0 2 66 1 2 5 426
The Impact of Reference Pricing of Cardiovascular Drugs on Health Care Costs and Health Outcomes: Evidence from British Columbia -- Volume II: Technical Report 0 0 1 39 0 1 2 169
The Impact of Reference Pricing of Cardiovascular Drugs on Health Care Costs and Health Outcomes: Evidence from British Columbia--Volume I: Summary 0 0 0 131 0 0 2 732
The Impact of Reference Pricing of Cardiovascular Drugs on Health Care Costs and Health Outcomes: Evidence from British Columbia--Volume II: Technical Report 0 0 1 68 0 0 1 289
The life expectancy gains from pharmaceutical drugs: a critical appraisal of the literature 0 0 0 192 0 0 3 702
Variance in Pharmacare Coverage Across Canada 0 0 0 32 1 1 3 214
Total Working Papers 1 2 24 3,369 4 17 96 15,036


Journal Article File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
A re‐examination of the impact of reference pricing on anti‐hypertensive drug plan expenditures in British Columbia 0 0 0 37 0 0 1 143
An empirical analysis of milk addiction 0 2 2 119 1 4 4 562
Differences in Incremental Cost-Effectiveness Ratios for Common Versus Rare Conditions: A Case from Oncology 0 0 0 1 0 0 1 10
Distributional effects of `general population' prescription drug programs in Canada 0 0 0 49 0 0 1 400
Distributional effects of ‘general population’ prescription drug programs in Canada 0 0 0 0 0 0 0 10
Do downturns cause desperation? The effect of economic conditions on suicide rates in Canada 0 0 0 25 0 0 2 102
Does rising income inequality affect mortality rates in advanced economies? 0 0 1 5 0 0 3 66
Estimating the price elasticity of expenditure for prescription drugs in the presence of non‐linear price schedules: an illustration from Quebec, Canada 0 1 4 338 0 2 9 1,609
Health care policy evaluation using longitudinal insurance claims data: An application of the Panel Tobit estimator 0 0 0 4 0 0 0 232
National Catastrophic Drug Insurance Revisited: Who Would Benefit from Senator Kirby's Recommendations? 0 0 0 21 0 2 2 282
Newton's First Law as Applied to Pharmacies: Why Entry Order Matters for Generics 0 2 6 32 1 4 10 120
On the evaluation of drug benefits policy changes with longitudinal claims data: the policy maker's versus the clinician's perspective 0 0 0 5 0 1 3 29
The cost of drug development: A systematic review 0 0 0 67 0 0 1 226
The effect of patented drug price on the share of new medicines across OECD countries 0 0 0 1 0 0 0 4
The effects of coxib formulary restrictions on analgesic use and cost: Regional evidence from Canada 0 0 0 3 0 0 0 63
The effects of drug subsidies on out-of-pocket prescription drug expenditures by seniors: regional evidence from Canada 0 0 0 49 0 0 2 275
Total Journal Articles 0 5 13 756 2 13 39 4,133


Chapter File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
Prescription Drug Insurance and Reimbursement 0 0 0 11 1 2 2 45
Prescription Drug Insurance and Reimbursement 0 0 0 18 0 1 2 51
Total Chapters 0 0 0 29 1 3 4 96


Statistics updated 2025-07-04